DIA_CENTRAL:T2D Treatment Pattern in Central Europe
CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries
Lead sponsor
Asset
GLP-1 / incretin class catch-all
Listed sites
177
Recruiting sites
-
Actual enrollment
4,083
Study population
Type 2 diabetes
Eligibility highlights
-
Primary endpoints
•Number of Patients in Each Category of First Prescription of a Respective•Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who•Baseline Characteristic
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Study population text
Adult patients (18 years of age or older) with Type 2 Diabetes diagnosis, naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), DPP4i (Dipeptidyl-peptidase 4 inhibitor) or GLP1a (Glucagon-like peptide 1 agonist) at index date were chosen.
Inclusion criteria
1. Written informed consent prior to participation
2. Female and male patients age ≥ 18 years
3. Patients with T2D diagnosis
4. Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
5. Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1
Exclusion criteria
1. Patients age < 18 years
2. Patients with diagnosis of other types of diabetes than T2D
3. Patients who do not provide written consent to the terms of the study
Endpoints (70)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Cardiovascular outcomes
8 endpointsNumber of Patients With Any Type of Cardiovascular Disease (CVD)
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
componentsMyocardial infarction (any), Coronary revascularization, Heart-failure hospitalization, Stroke (any), Peripheral-artery outcome composite
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| T2D Patients From Central Eastern Europe | 1485 | - |
Number of Patients in Each Category of the Different Types of Cardiovascular Disease
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| T2D Patients From Central Eastern EuropeMyocardial infarction | 450 | - |
| Myocardial infarction | 3558 | - |
| Myocardial infarction | 47 | - |
| Cardiology intervention (PCI or CABG) | 525 | - |
| Cardiology intervention (PCI or CABG) | 3471 | - |
| Cardiology intervention (PCI or CABG) | 59 | - |
| Ischemic heart disease | 1087 | - |
| Ischemic heart disease | 2910 | - |
| Ischemic heart disease | 58 | - |
| Congestive heart failure | 421 | - |
| Congestive heart failure | 3511 | - |
| Congestive heart failure | 123 | - |
| Stroke | 248 | - |
| Stroke | 3764 | - |
| Stroke | 43 | - |
| Peripheral arterial disease | 350 | - |
| Peripheral arterial disease | 3643 | - |
| Peripheral arterial disease | 62 | - |
Number of Patients With Any Type of Cardiovascular Disease (CVD) and Without CVD According to Prescribing Specialist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on T2D Medication by Endocrinologist | 736 | - |
| 916 | - | |
| Patients Initiated on T2D Medication by Diabetologist | 656 | - |
| 1645 | - | |
| Patients Initiated on T2D Medication by Cardiologist | 93 | - |
| 9 | - |
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 812 | - |
| 1154 | - | |
| Patients Initiated on DPP4i | 398 | - |
| 746 | - | |
| Patients Initiated on GLP-1 RA | 75 | - |
| 286 | - | |
| Patients Initiated on Other SGLT2i | 200 | - |
| 384 | - |
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on EmpagliflozinMyocardial infarction | 276 | - |
| Myocardial infarction | 1667 | - |
| Myocardial infarction | 23 | - |
| Cardiology intervention (PCI or CABG) | 328 | - |
| Cardiology intervention (PCI or CABG) | 1614 | - |
| Cardiology intervention (PCI or CABG) | 24 | - |
| Ischemic heart disease | 631 | - |
| Ischemic heart disease | 1312 | - |
| Ischemic heart disease | 23 | - |
| Congestive heart failure | 252 | - |
| Congestive heart failure | 1664 | - |
| Congestive heart failure | 50 | - |
| Stroke | 128 | - |
| Stroke | 1819 | - |
| Stroke | 19 | - |
| Peripheral arterial disease | 171 | - |
| Peripheral arterial disease | 1767 | - |
| Peripheral arterial disease | 28 | - |
| Patients Initiated on DPP4iMyocardial infarction | 91 | - |
| Myocardial infarction | 1039 | - |
| Myocardial infarction | 14 | - |
| Cardiology intervention (PCI or CABG) | 98 | - |
| Cardiology intervention (PCI or CABG) | 1024 | - |
| Cardiology intervention (PCI or CABG) | 22 | - |
| Ischemic heart disease | 265 | - |
| Ischemic heart disease | 860 | - |
| Ischemic heart disease | 19 | - |
| Congestive heart failure | 104 | - |
| Congestive heart failure | 997 | - |
| Congestive heart failure | 43 | - |
| Stroke | 76 | - |
| Stroke | 1056 | - |
| Stroke | 12 | - |
| Peripheral arterial disease | 118 | - |
| Peripheral arterial disease | 1008 | - |
| Peripheral arterial disease | 18 | - |
| Patients Initiated on GLP-1 RAMyocardial infarction | 22 | - |
| Myocardial infarction | 334 | - |
| Myocardial infarction | 5 | - |
| Cardiology intervention (PCI or CABG) | 30 | - |
| Cardiology intervention (PCI or CABG) | 324 | - |
| Cardiology intervention (PCI or CABG) | 7 | - |
| Ischemic heart disease | 50 | - |
| Ischemic heart disease | 305 | - |
| Ischemic heart disease | 6 | - |
| Congestive heart failure | 14 | - |
| Congestive heart failure | 337 | - |
| Congestive heart failure | 10 | - |
| Stroke | 12 | - |
| Stroke | 342 | - |
| Stroke | 7 | - |
| Peripheral arterial disease | 15 | - |
| Peripheral arterial disease | 339 | - |
| Peripheral arterial disease | 7 | - |
| Patients Initiated on Other SGLT2iMyocardial infarction | 61 | - |
| Myocardial infarction | 518 | - |
| Myocardial infarction | 5 | - |
| Cardiology intervention (PCI or CABG) | 69 | - |
| Cardiology intervention (PCI or CABG) | 509 | - |
| Cardiology intervention (PCI or CABG) | 6 | - |
| Ischemic heart disease | 141 | - |
| Ischemic heart disease | 433 | - |
| Ischemic heart disease | 10 | - |
| Congestive heart failure | 51 | - |
| Congestive heart failure | 513 | - |
| Congestive heart failure | 20 | - |
| Stroke | 32 | - |
| Stroke | 547 | - |
| Stroke | 5 | - |
| Peripheral arterial disease | 46 | - |
| Peripheral arterial disease | 529 | - |
| Peripheral arterial disease | 9 | - |
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication From by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 380 | - |
| 435 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 229 | - |
| 275 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 28 | - |
| 61 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 99 | - |
| 145 | - |
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 362 | - |
| 711 | - | |
| Patients Initiated on DPP4i by Diabetologist | 154 | - |
| 470 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 46 | - |
| 225 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 94 | - |
| 239 | - |
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
componentsMyocardial infarction (any), Coronary revascularization, Stroke (any), Heart-failure hospitalization, Peripheral-artery outcome composite
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 70 | - |
| 8 | - | |
| Patients Initiated on DPP4i by Cardiologist | 15 | - |
| 1 | - | |
| Patients Initiated on GLP-1 RA by Cardiologist | 1 | - |
| 0 | - | |
| Patients Initiated on Other SGLT2i by Cardiologist | 7 | - |
| 0 | - |
Weight & body composition
3 endpointsBaseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
BMI, change
descriptive
Posted result
| Group | Mean · kilogram/meter^2 (kg/m^2) | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 33.3 | - |
| Patients Initiated on DPP4i by Endocrinologist | 31.3 | - |
| Patients Initiated on GLP-1 RA by Endocrinologist | 36.7 | - |
| Patients Initiated on Other SGLT2i by Endocrinologist | 34.3 | - |
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
BMI, change
descriptive
Posted result
| Group | Mean · kilogram/meter^2 (kg/m^2) | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 33.3 | - |
| Patients Initiated on DPP4i by Diabetologist | 31.0 | - |
| Patients Initiated on GLP-1 RA by Diabetologist | 36.2 | - |
| Patients Initiated on Other SGLT2i by Diabetologist | 32.8 | - |
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
BMI, change
descriptive
Posted result
| Group | Mean · kilogram/meter^2 (kg/m^2) | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 30.8 | - |
| Patients Initiated on DPP4i by Cardiologist | 29.9 | - |
| Patients Initiated on GLP-1 RA by Cardiologist | 25.8 | - |
| Patients Initiated on Other SGLT2i by Cardiologist | 30.7 | - |
Glycemic / diabetes
15 endpointsBaseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Mean · Years | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 61.5 | - |
| Patients Initiated on DPP4i by Endocrinologist | 65.3 | - |
| Patients Initiated on GLP-1 RA by Endocrinologist | 55.8 | - |
| Patients Initiated on Other SGLT2i by Endocrinologist | 62.0 | - |
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 433 | - |
| 640 | - | |
| Patients Initiated on DPP4i by Diabetologist | 297 | - |
| 327 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 135 | - |
| 136 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 140 | - |
| 193 | - |
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Mean · Years | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 9.1 | - |
| Patients Initiated on DPP4i by Endocrinologist | 9.1 | - |
| Patients Initiated on GLP-1 RA by Endocrinologist | 9.2 | - |
| Patients Initiated on Other SGLT2i by Endocrinologist | 9.8 | - |
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Mean · Years | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 10.7 | - |
| Patients Initiated on DPP4i by Diabetologist | 10.4 | - |
| Patients Initiated on GLP-1 RA by Diabetologist | 10.1 | - |
| Patients Initiated on Other SGLT2i by Diabetologist | 10.1 | - |
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive, improvement
LOINC 4548-4
Posted result
| Group | Mean · percentage of glycosylated hemoglobin | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 8.5 | - |
| Patients Initiated on DPP4i by Endocrinologist | 8.1 | - |
| Patients Initiated on GLP-1 RA by Endocrinologist | 8.2 | - |
| Patients Initiated on Other SGLT2i by Endocrinologist | 8.5 | - |
Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
LOINC 4548-4
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 453 | - |
| 349 | - | |
| 13 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 339 | - |
| 138 | - | |
| 27 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 56 | - |
| 29 | - | |
| 4 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 138 | - |
| 97 | - | |
| 9 | - |
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
LOINC 4548-4
Posted result
| Group | Mean · percentage of glycosylated hemoglobin | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 8.2 | - |
| Patients Initiated on DPP4i by Diabetologist | 7.9 | - |
| Patients Initiated on GLP-1 RA by Diabetologist | 8.4 | - |
| Patients Initiated on Other SGLT2i by Diabetologist | 8.6 | - |
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
threshold achievement, improvement
LOINC 4548-4
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 642 | - |
| 278 | - | |
| 153 | - | |
| Patients Initiated on DPP4i by Diabetologist | 453 | - |
| 123 | - | |
| 48 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 162 | - |
| 95 | - | |
| 14 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 183 | - |
| 114 | - | |
| 36 | - |
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
LOINC 4548-4
Posted result
| Group | Mean · percentage of glycosylated hemoglobin | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 7.9 | - |
| Patients Initiated on DPP4i by Cardiologist | 8.1 | - |
| Patients Initiated on GLP-1 RA by Cardiologist | 7.4 | - |
| Patients Initiated on Other SGLT2i by Cardiologist | 8.5 | - |
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
LOINC 4548-4
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 36 | - |
| 14 | - | |
| 28 | - | |
| Patients Initiated on DPP4i by Cardiologist | 11 | - |
| 4 | - | |
| 1 | - | |
| Patients Initiated on GLP-1 RA by Cardiologist | 1 | - |
| 0 | - | |
| 0 | - | |
| Patients Initiated on Other SGLT2i by Cardiologist | 3 | - |
| 2 | - | |
| 2 | - |
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 134 | - |
| 1563 | - | |
| Patients Initiated on DPP4i | 129 | - |
| 924 | - | |
| Patients Initiated on GLP-1 RA | 38 | - |
| 294 | - | |
| Patients Initiated on Other SGLT2i | 60 | - |
| 476 | - |
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 42 | - |
| 689 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 58 | - |
| 421 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 17 | - |
| 64 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 26 | - |
| 188 | - |
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 87 | - |
| 819 | - | |
| Patients Initiated on DPP4i by Diabetologist | 71 | - |
| 490 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 21 | - |
| 229 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 34 | - |
| 282 | - |
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
T2D MED STATUS CATEGORICAL
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 5 | - |
| 55 | - | |
| Patients Initiated on DPP4i by Cardiologist | 0 | - |
| 13 | - | |
| Patients Initiated on GLP-1 RA by Cardiologist | 0 | - |
| 1 | - | |
| Patients Initiated on Other SGLT2i by Cardiologist | 0 | - |
| 6 | - |
Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication
Time frame:From date of first prescription (study index date 1) to stop date of initial type 2 diabetes (T2D)) medication (documented at index date 2), up to 14 months..
time to event, improvement
Posted result
| Group | Mean · months | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 19.46 | - |
| Patients Initiated on DPP4i | 18.28 | - |
| Patients Initiated on GLP-1 RA | 20.61 | - |
| Patients Initiated on Other SGLT2i | 14.04 | - |
Heart failure
2 endpointsNumber of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
SNOMED 84114007
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| T2D Patients From Central Eastern Europe | 245 | - |
| 86 | - | |
| 90 | - |
Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
SNOMED 84114007
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 164 | - |
| 36 | - | |
| 52 | - | |
| Patients Initiated on DPP4i | 42 | - |
| 39 | - | |
| 23 | - | |
| Patients Initiated on GLP-1 RA | 9 | - |
| 4 | - | |
| 1 | - | |
| Patients Initiated on Other SGLT2i | 30 | - |
| 7 | - | |
| 14 | - |
Renal / kidney
7 endpointsNumber of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| T2D Patients From Central Eastern Europe | 586 | - |
Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| T2D Patients From Central Eastern Europe | 3175 | - |
Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| T2D Patients From Central Eastern Europe | 886 | - |
Number of Patients With Chronic Kidney (CKD) (Patients for Whom CKD Was Reported as a Comorbidity) or Without CKD by Physician's Assessment According to Prescribing Specialist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on T2D Medication by Endocrinologist | 327 | - |
| 1325 | - | |
| Patients Initiated on T2D Medication by Diabetologist | 244 | - |
| 2057 | - | |
| Patients Initiated on T2D Medication by Cardiologist | 15 | - |
| 87 | - |
Number of Patients With Chronic Kidney Disease (CKD) by eGFR and UACR Status According to Prescribing Specialist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on T2D Medication by Endocrinologist | 508 | - |
| Patients Initiated on T2D Medication by Diabetologist | 358 | - |
| Patients Initiated on T2D Medication by Cardiologist | 20 | - |
Number of Patients With Chronic Kidney (CKD) or Without CKD by Physician's Assessment According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 221 | - |
| 1745 | - | |
| Patients Initiated on DPP4i | 289 | - |
| 855 | - | |
| Patients Initiated on GLP-1 RA | 26 | - |
| 335 | - | |
| Patients Initiated on Other SGLT2i | 50 | - |
| 534 | - |
Number of Patients With Chronic Kidney (CKD) and Without CKD by eGFR and UACR Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 386 | - |
| 1182 | - | |
| Patients Initiated on DPP4i | 365 | - |
| 542 | - | |
| Patients Initiated on GLP-1 RA | 50 | - |
| 215 | - | |
| Patients Initiated on Other SGLT2i | 85 | - |
| 350 | - |
Cardiometabolic biomarkers
3 endpoints10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Mean · Score on a scale | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 6.4 | - |
| Patients Initiated on DPP4i by Endocrinologist | 5.6 | - |
| Patients Initiated on GLP-1 RA by Endocrinologist | 4.3 | - |
| Patients Initiated on Other SGLT2i by Endocrinologist | 6.0 | - |
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Mean · Score on a scale | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 7.0 | - |
| Patients Initiated on DPP4i by Diabetologist | 7.0 | - |
| Patients Initiated on GLP-1 RA by Diabetologist | 5.4 | - |
| Patients Initiated on Other SGLT2i by Diabetologist | 6.5 | - |
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive, improvement
Posted result
| Group | Mean · Score on a scale | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 8.9 | - |
| Patients Initiated on DPP4i by Cardiologist | 9.4 | - |
| Patients Initiated on GLP-1 RA by Cardiologist | 5.0 | - |
| Patients Initiated on Other SGLT2i by Cardiologist | 3.8 | - |
Safety / tolerability / PK
5 endpointsNumber of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Discontinuation due to AE
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| T2D Patients From Bulgaria | 17 | - |
| 1 | - | |
| 2 | - | |
| 0 | - | |
| 3 | - | |
| 2 | - | |
| T2D Patients From Czech Republic | 64 | - |
| 1 | - | |
| 0 | - | |
| 3 | - | |
| 9 | - | |
| 13 | - | |
| T2D Patients From Hungary | 9 | - |
| 0 | - | |
| 2 | - | |
| 1 | - | |
| 1 | - | |
| 3 | - | |
| T2D Patients From Poland | 15 | - |
| 1 | - | |
| 58 | - | |
| 5 | - | |
| 23 | - | |
| 2 | - | |
| T2D Patients From Russian Federation | 30 | - |
| 16 | - | |
| 60 | - | |
| 1 | - | |
| 7 | - | |
| 12 | - |
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Discontinuation due to AE
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 29 | - |
| 8 | - | |
| 49 | - | |
| 5 | - | |
| 32 | - | |
| 11 | - | |
| Patients Initiated on DPP4i | 67 | - |
| 7 | - | |
| 37 | - | |
| 3 | - | |
| 0 | - | |
| 15 | - | |
| Patients Initiated on GLP-1 RA | 20 | - |
| 1 | - | |
| 9 | - | |
| 0 | - | |
| 3 | - | |
| 5 | - | |
| Patients Initiated on Other SGLT2i | 19 | - |
| 3 | - | |
| 27 | - | |
| 2 | - | |
| 8 | - | |
| 1 | - |
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Discontinuation due to AE
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 10 | - |
| 6 | - | |
| 15 | - | |
| 1 | - | |
| 2 | - | |
| 8 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 26 | - |
| 6 | - | |
| 24 | - | |
| 0 | - | |
| 0 | - | |
| 2 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 6 | - |
| 0 | - | |
| 7 | - | |
| 0 | - | |
| 2 | - | |
| 2 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 2 | - |
| 3 | - | |
| 14 | - | |
| 0 | - | |
| 6 | - | |
| 1 | - |
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Discontinuation due to AE
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 17 | - |
| 0 | - | |
| 34 | - | |
| 4 | - | |
| 30 | - | |
| 2 | - | |
| Patients Initiated on DPP4i by Diabetologist | 41 | - |
| 1 | - | |
| 13 | - | |
| 3 | - | |
| 0 | - | |
| 13 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 14 | - |
| 1 | - | |
| 2 | - | |
| 0 | - | |
| 1 | - | |
| 3 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 17 | - |
| 0 | - | |
| 13 | - | |
| 2 | - | |
| 2 | - | |
| 0 | - |
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
Discontinuation due to AE
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 2 | - |
| 2 | - | |
| 0 | - | |
| 0 | - | |
| 0 | - | |
| 1 | - |
Other clinical outcomes
23 endpointsNumber of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on T2D Medication by Endocrinologist | 815 | - |
| 244 | - | |
| 504 | - | |
| 89 | - | |
| Patients Initiated on T2D Medication by Diabetologist | 1073 | - |
| 333 | - | |
| 624 | - | |
| 271 | - | |
| Patients Initiated on T2D Medication by Cardiologist | 78 | - |
| 7 | - | |
| 16 | - | |
| 1 | - |
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on T2D Medication by EndocrinologistMetformin | 1349 | - |
| Sulfonylurea | 626 | - |
| Acarbose | 3 | - |
| Pioglitazone | 3 | - |
| Insulin | 342 | - |
| Others | 59 | - |
| Patients Initiated on T2D Medication by DiabetologistMetformin | 1794 | - |
| Sulfonylurea | 513 | - |
| Acarbose | 49 | - |
| Pioglitazone | 91 | - |
| Insulin | 658 | - |
| Others | 91 | - |
| Patients Initiated on T2D Medication by CardiologistMetformin | 81 | - |
| Sulfonylurea | 17 | - |
| Acarbose | 3 | - |
| Pioglitazone | 0 | - |
| Insulin | 17 | - |
| Others | 7 | - |
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on T2D Medication by EndocrinologistAntihypertensive ACEi or ARBs | 1256 | - |
| Statins | 983 | - |
| Low dose aspirin | 555 | - |
| Beta blockers | 580 | - |
| Diuretics | 471 | - |
| Others | 160 | - |
| Patients Initiated on T2D Medication by DiabetologistAntihypertensive ACEi or ARBs | 1536 | - |
| Statins | 1327 | - |
| Low dose aspirin | 622 | - |
| Beta blockers | 922 | - |
| Diuretics | 732 | - |
| Others | 455 | - |
| Patients Initiated on T2D Medication by CardiologistAntihypertensive ACEi or ARBs | 87 | - |
| Statins | 82 | - |
| Low dose aspirin | 64 | - |
| Beta blockers | 73 | - |
| Diuretics | 44 | - |
| Others | 29 | - |
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 432 | - |
| 383 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 334 | - |
| 170 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 37 | - |
| 52 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 140 | - |
| 104 | - |
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 10 | - |
| 805 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 7 | - |
| 497 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 1 | - |
| 88 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 5 | - |
| 239 | - |
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Mean · Years | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 63.0 | - |
| Patients Initiated on DPP4i by Diabetologist | 67.2 | - |
| Patients Initiated on GLP-1 RA by Diabetologist | 59.2 | - |
| Patients Initiated on Other SGLT2i by Diabetologist | 62.3 | - |
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
age baseline by medication type
descriptive
Posted result
| Group | Mean · Years | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 64.4 | - |
| Patients Initiated on DPP4i by Cardiologist | 70.9 | - |
| Patients Initiated on GLP-1 RA by Cardiologist | 54.0 | - |
| Patients Initiated on Other SGLT2i by Cardiologist | 65.0 | - |
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 0 | - |
| 78 | - | |
| Patients Initiated on DPP4i by Cardiologist | 0 | - |
| 16 | - | |
| Patients Initiated on GLP-1 RA by Cardiologist | 0 | - |
| 1 | - | |
| Patients Initiated on Other SGLT2i by Cardiologist | 0 | - |
| 7 | - |
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Mean · Years | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 6.7 | - |
| Patients Initiated on DPP4i by Cardiologist | 9.7 | - |
| Patients Initiated on GLP-1 RA by Cardiologist | 6.0 | - |
| Patients Initiated on Other SGLT2i by Cardiologist | 10.9 | - |
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
patient count by physician specialty
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by EndocrinologistOther endocrinologist | 56 | - |
| Diabetologist | 0 | - |
| Cardiologist | 81 | - |
| Nephrologist | 8 | - |
| General practitioner | 46 | - |
| Others | 3 | - |
| None | 697 | - |
| Patients Initiated on DPP4i by EndocrinologistOther endocrinologist | 36 | - |
| Diabetologist | 0 | - |
| Cardiologist | 25 | - |
| Nephrologist | 8 | - |
| General practitioner | 33 | - |
| Others | 5 | - |
| None | 439 | - |
| Patients Initiated on GLP-1 RA by EndocrinologistOther endocrinologist | 1 | - |
| Diabetologist | 0 | - |
| Cardiologist | 7 | - |
| Nephrologist | 2 | - |
| General practitioner | 7 | - |
| Others | 3 | - |
| None | 76 | - |
| Patients Initiated on Other SGLT2i by EndocrinologistOther endocrinologist | 11 | - |
| Diabetologist | 0 | - |
| Cardiologist | 19 | - |
| Nephrologist | 0 | - |
| General practitioner | 12 | - |
| Others | 1 | - |
| None | 209 | - |
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by DiabetologistEndocrinologist | 3 | - |
| Other diabetologist | 74 | - |
| Cardiologist | 35 | - |
| Nephrologist | 1 | - |
| General practitioner | 25 | - |
| Others | 0 | - |
| None | 953 | - |
| Patients Initiated on DPP4i by DiabetologistEndocrinologist | 0 | - |
| Other diabetologist | 35 | - |
| Cardiologist | 2 | - |
| Nephrologist | 5 | - |
| General practitioner | 6 | - |
| Others | 1 | - |
| None | 577 | - |
| Patients Initiated on GLP-1 RA by DiabetologistEndocrinologist | 0 | - |
| Other diabetologist | 11 | - |
| Cardiologist | 2 | - |
| Nephrologist | 0 | - |
| General practitioner | 1 | - |
| Others | 0 | - |
| None | 257 | - |
| Patients Initiated on Other SGLT2i by DiabetologistEndocrinologist | 0 | - |
| Other diabetologist | 24 | - |
| Cardiologist | 3 | - |
| Nephrologist | 0 | - |
| General practitioner | 7 | - |
| Others | 1 | - |
| None | 300 | - |
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
specialty count
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by CardiologistEndocrinologist | 19 | - |
| Diabetologist | 10 | - |
| Other cardiologist | 4 | - |
| Nephrologist | 1 | - |
| General practitioner | 0 | - |
| Others | 0 | - |
| None | 45 | - |
| Patients Initiated on DPP4i by CardiologistEndocrinologist | 0 | - |
| Diabetologist | 1 | - |
| Other cardiologist | 0 | - |
| Nephrologist | 3 | - |
| General practitioner | 0 | - |
| Others | 0 | - |
| None | 12 | - |
| Patients Initiated on GLP-1 RA by CardiologistEndocrinologist | 0 | - |
| Diabetologist | 0 | - |
| Other cardiologist | 0 | - |
| Nephrologist | 0 | - |
| General practitioner | 0 | - |
| Others | 0 | - |
| None | 1 | - |
| Patients Initiated on Other SGLT2i by CardiologistEndocrinologist | 0 | - |
| Diabetologist | 0 | - |
| Other cardiologist | 0 | - |
| Nephrologist | 0 | - |
| General practitioner | 0 | - |
| Others | 0 | - |
| None | 7 | - |
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 966 | - |
| 878 | - | |
| 122 | - | |
| Patients Initiated on DPP4i | 433 | - |
| 639 | - | |
| 72 | - | |
| Patients Initiated on GLP-1 RA | 229 | - |
| 111 | - | |
| 21 | - | |
| Patients Initiated on Other SGLT2i | 302 | - |
| 261 | - | |
| 21 | - |
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 124 | - |
| 1339 | - | |
| 88 | - | |
| 143 | - | |
| 272 | - | |
| Patients Initiated on DPP4i | 86 | - |
| 668 | - | |
| 59 | - | |
| 147 | - | |
| 184 | - | |
| Patients Initiated on GLP-1 RA | 26 | - |
| 252 | - | |
| 27 | - | |
| 19 | - | |
| 37 | - | |
| Patients Initiated on Other SGLT2i | 42 | - |
| 411 | - | |
| 37 | - | |
| 31 | - | |
| 63 | - |
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin | 50 | - |
| 1725 | - | |
| 89 | - | |
| 102 | - | |
| Patients Initiated on DPP4i | 13 | - |
| 1055 | - | |
| 35 | - | |
| 41 | - | |
| Patients Initiated on GLP-1 RA | 3 | - |
| 336 | - | |
| 13 | - | |
| 9 | - | |
| Patients Initiated on Other SGLT2i | 11 | - |
| 539 | - | |
| 16 | - | |
| 18 | - |
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 438 | - |
| 345 | - | |
| 32 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 199 | - |
| 286 | - | |
| 19 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 69 | - |
| 17 | - | |
| 3 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 128 | - |
| 109 | - | |
| 7 | - |
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 55 | - |
| 566 | - | |
| 44 | - | |
| 67 | - | |
| 83 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 52 | - |
| 290 | - | |
| 27 | - | |
| 69 | - | |
| 66 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 7 | - |
| 68 | - | |
| 5 | - | |
| 2 | - | |
| 7 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 22 | - |
| 175 | - | |
| 6 | - | |
| 9 | - | |
| 32 | - |
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
insurance status by medication class
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Endocrinologist | 40 | - |
| 630 | - | |
| 82 | - | |
| 63 | - | |
| Patients Initiated on DPP4i by Endocrinologist | 12 | - |
| 438 | - | |
| 34 | - | |
| 20 | - | |
| Patients Initiated on GLP-1 RA by Endocrinologist | 3 | - |
| 73 | - | |
| 13 | - | |
| 0.0 | - | |
| Patients Initiated on Other SGLT2i by Endocrinologist | 11 | - |
| 208 | - | |
| 16 | - | |
| 9 | - |
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 491 | - |
| 500 | - | |
| 82 | - | |
| Patients Initiated on DPP4i by Diabetologist | 228 | - |
| 345 | - | |
| 51 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 159 | - |
| 94 | - | |
| 18 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 171 | - |
| 150 | - | |
| 12 | - |
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 2 | - |
| 1039 | - | |
| 3 | - | |
| 29 | - | |
| Patients Initiated on DPP4i by Diabetologist | 1 | - |
| 603 | - | |
| 1 | - | |
| 19 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 0.0 | - |
| 262 | - | |
| 0.0 | - | |
| 9 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 0.0 | - |
| 326 | - | |
| 0 | - | |
| 7 | - |
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 37 | - |
| 33 | - | |
| 8 | - | |
| Patients Initiated on DPP4i by Cardiologist | 6 | - |
| 8 | - | |
| 2 | - | |
| Patients Initiated on GLP-1 RA by Cardiologist | 1 | - |
| 0 | - | |
| 0 | - | |
| Patients Initiated on Other SGLT2i by Cardiologist | 3 | - |
| 2 | - | |
| 2 | - |
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 13 | - |
| 46 | - | |
| 6 | - | |
| 5 | - | |
| 8 | - | |
| Patients Initiated on DPP4i by Cardiologist | 1 | - |
| 10 | - | |
| 1 | - | |
| 2 | - | |
| 2 | - | |
| Patients Initiated on GLP-1 RA by Cardiologist | 0 | - |
| 1 | - | |
| 0 | - | |
| 0 | - | |
| 0 | - | |
| Patients Initiated on Other SGLT2i by Cardiologist | 1 | - |
| 3 | - | |
| 0 | - | |
| 1 | - | |
| 2 | - |
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
categorical status, descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 8 | - |
| 56 | - | |
| 4 | - | |
| 10 | - | |
| Patients Initiated on DPP4i by Cardiologist | 0 | - |
| 14 | - | |
| 0 | - | |
| 2 | - | |
| Patients Initiated on GLP-1 RA by Cardiologist | 0 | - |
| 1 | - | |
| 0 | - | |
| 0 | - | |
| Patients Initiated on Other SGLT2i by Cardiologist | 0 | - |
| 5 | - | |
| 0 | - | |
| 2 | - |
Other (unclassified)
4 endpointsBaseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 3 | - |
| 1070 | - | |
| Patients Initiated on DPP4i by Diabetologist | 0 | - |
| 624 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 1 | - |
| 270 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 0 | - |
| 333 | - |
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Cardiologist | 35 | - |
| 43 | - | |
| Patients Initiated on DPP4i by Cardiologist | 8 | - |
| 8 | - | |
| Patients Initiated on GLP-1 RA by Cardiologist | 0 | - |
| 1 | - | |
| Patients Initiated on Other SGLT2i by Cardiologist | 2 | - |
| 5 | - |
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
Time frame:At study index date 1 (i.e. between September 2018 and December 2018).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on Empagliflozin by Diabetologist | 56 | - |
| 727 | - | |
| 38 | - | |
| 71 | - | |
| 181 | - | |
| Patients Initiated on DPP4i by Diabetologist | 33 | - |
| 368 | - | |
| 31 | - | |
| 76 | - | |
| 116 | - | |
| Patients Initiated on GLP-1 RA by Diabetologist | 19 | - |
| 183 | - | |
| 22 | - | |
| 17 | - | |
| 30 | - | |
| Patients Initiated on Other SGLT2i by Diabetologist | 19 | - |
| 233 | - | |
| 31 | - | |
| 21 | - | |
| 29 | - |
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
Time frame:At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
descriptive
Posted result
| Group | Participants | 95% CI |
|---|---|---|
| Patients Initiated on T2D Medication by EndocrinologistEndocrinologist | 26 | - |
| Diabetologist | 0 | - |
| Cardiologist | 2 | - |
| General practitioner | 14 | - |
| Other | 2 | - |
| None | 102 | - |
| Patients Initiated on T2D Medication by DiabetologistEndocrinologist | 0 | - |
| Diabetologist | 2 | - |
| Cardiologist | 0 | - |
| General practitioner | 23 | - |
| Other | 3 | - |
| None | 185 | - |
| Patients Initiated on T2D Medication by CardiologistEndocrinologist | 4 | - |
| Diabetologist | 0 | - |
| Cardiologist | 0 | - |
| General practitioner | 1 | - |
| Other | 0 | - |
| None | 0 | - |
Publications (1)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- Cardiovascular diabetology2022 Oct 8PMID36209118doi:10.1186/s12933-022-01631-4via clinicaltrials gov reference derived + pubmed nct search
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.